A plant-derived cocaine hydrolase prevents cocaine overdose lethality and attenuates cocaine-induced drug seeking behavior.


Journal

Progress in neuro-psychopharmacology & biological psychiatry
ISSN: 1878-4216
Titre abrégé: Prog Neuropsychopharmacol Biol Psychiatry
Pays: England
ID NLM: 8211617

Informations de publication

Date de publication:
30 08 2020
Historique:
received: 25 11 2019
revised: 01 05 2020
accepted: 02 05 2020
pubmed: 11 5 2020
medline: 8 6 2021
entrez: 11 5 2020
Statut: ppublish

Résumé

Cocaine use disorders include short-term and acute pathologies (e.g. overdose) and long-term and chronic disorders (e.g. intractable addiction and post-abstinence relapse). There is currently no available treatment that can effectively reduce morbidity and mortality associated with cocaine overdose or that can effectively prevent relapse in recovering addicts. One recently developed approach to treat these problems is the use of enzymes that rapidly break down the active cocaine molecule into inactive metabolites. In particular, rational design and site-directed mutagenesis transformed human serum recombinant butyrylcholinesterase (BChE) into a highly efficient cocaine hydrolase with drastically improved catalytic efficiency toward (-)-cocaine. A current drawback preventing the clinical application of this promising enzyme-based therapy is the lack of a cost-effective production strategy that is also flexible enough to rapidly scale-up in response to continuous improvements in enzyme design. Plant-based expression systems provide a unique solution as this platform is designed for fast scalability, low cost and the advantage of performing eukaryotic protein modifications such as glycosylation. A Plant-derived form of the Cocaine Super Hydrolase (A199S/F227A/S287G/A328W/Y332G) we designate PCocSH protects mice from cocaine overdose, counters the lethal effects of acute cocaine overdose, and prevents reinstatement of extinguished drug-seeking behavior in mice that underwent place conditioning with cocaine. These results demonstrate that the novel PCocSH enzyme may well serve as an effective therapeutic for cocaine use disorders in a clinical setting.

Identifiants

pubmed: 32387315
pii: S0278-5846(20)30277-3
doi: 10.1016/j.pnpbp.2020.109961
pmc: PMC7398606
mid: NIHMS1595384
pii:
doi:

Substances chimiques

Recombinant Proteins 0
Carboxylic Ester Hydrolases EC 3.1.1.-
Butyrylcholinesterase EC 3.1.1.8
cocaine hydrolase EC 3.1.1.8
Cocaine I5Y540LHVR

Types de publication

Journal Article Research Support, N.I.H., Extramural

Langues

eng

Sous-ensembles de citation

IM

Pagination

109961

Subventions

Organisme : NIDA NIH HHS
ID : DP1 DA031340
Pays : United States
Organisme : NIDA NIH HHS
ID : R01 DA011064
Pays : United States
Organisme : NIDA NIH HHS
ID : UH2 DA041115
Pays : United States
Organisme : NIDA NIH HHS
ID : UH3 DA041115
Pays : United States

Informations de copyright

Copyright © 2020 Elsevier Inc. All rights reserved.

Déclaration de conflit d'intérêts

Declaration of Competing Interest KEL, LK, SB, C-GZ, JN and TSM are listed as inventors in various patents and patent applications relating to various aspects of the presented data. All other authors (RPK, TJ, MB, KS, and JK) declare no conflict of interest.

Références

Nat Med. 1996 Oct;2(10):1129-32
pubmed: 8837612
J Pharmacol Exp Ther. 2007 Feb;320(2):926-33
pubmed: 17114567
Biophys J. 2009 Mar 4;96(5):1931-8
pubmed: 19254552
Front Syst Neurosci. 2017 Oct 10;11:73
pubmed: 29066957
Plant Biotechnol J. 2014 Sep;12(7):832-9
pubmed: 24618259
Neurobiol Learn Mem. 2007 Jan;87(1):93-100
pubmed: 16905344
Life Sci. 1977 May 1;20(9):1557-63
pubmed: 17804
Mol Pharmacol. 2002 Aug;62(2):220-4
pubmed: 12130672
Drug Alcohol Depend. 2016 Nov 01;168:287-292
pubmed: 27736682
Sci Rep. 2017 Sep 5;7(1):10419
pubmed: 28874829
J Pharmacol Exp Ther. 1987 Oct;243(1):144-9
pubmed: 3668848
Biotechnol Lett. 2015 Nov;37(11):2147-50
pubmed: 26149580
Psychopharmacology (Berl). 2011 Feb;213(4):817-29
pubmed: 20972552
Mol Pharmacol. 2006 Dec;70(6):1885-91
pubmed: 16968810
J Pharmacol Exp Ther. 2013 Nov;347(2):251-7
pubmed: 23978563
Psychopharmacology (Berl). 1989;97(1):59-64
pubmed: 2496428
Proc Natl Acad Sci U S A. 2005 Nov 15;102(46):16656-61
pubmed: 16275916
Future Med Chem. 2012 Feb;4(2):227-43
pubmed: 22300100
Sci Rep. 2017 Nov 10;7(1):15303
pubmed: 29127295
Clin Pharmacol Ther. 1978 May;23(5):547-52
pubmed: 639429
Biotechnol Adv. 2016 Sep-Oct;34(5):597-604
pubmed: 26875776
Neuropsychopharmacology. 2008 Oct;33(11):2715-25
pubmed: 18199998
Proc Natl Acad Sci U S A. 2015 Feb 17;112(7):2251-6
pubmed: 25646463
J Clin Psychopharmacol. 2015 Aug;35(4):396-405
pubmed: 26082975
J Pharmacol Exp Ther. 1993 Oct;267(1):296-307
pubmed: 8229755
Chem Biol Interact. 2013 Mar 25;203(1):217-20
pubmed: 23000451
Drug Alcohol Depend. 2016 Sep 01;166:13-20
pubmed: 27394932
Nat Commun. 2014 Mar 18;5:3457
pubmed: 24643289
J Clin Pharmacol. 2015 May;55(5):573-83
pubmed: 25524052
Chem Biol Interact. 2013 Mar 25;203(1):57-62
pubmed: 22917637
CNS Neurol Disord Drug Targets. 2015;14(6):773-6
pubmed: 26073938
Behav Brain Res. 2000 Oct;115(1):39-47
pubmed: 10996406
Chem Biol Interact. 2010 Sep 6;187(1-3):148-52
pubmed: 20060817
Lancet. 2019 Nov 2;394(10209):1652-1667
pubmed: 31668409
Psychopharmacology (Berl). 1981;75(2):134-43
pubmed: 6798603
Arch Gen Psychiatry. 2009 Oct;66(10):1116-23
pubmed: 19805702
Future Med Chem. 2011 Jan;3(1):9-13
pubmed: 21428822
Int J Mol Sci. 2019 Jan 29;20(3):
pubmed: 30700023
Mol Pharmacol. 2011 Feb;79(2):290-7
pubmed: 20971807
Neuropsychopharmacology. 2002 Jan;26(1):130-4
pubmed: 11751040
J Pharmacol Exp Ther. 2002 Aug;302(2):710-6
pubmed: 12130735
Biol Psychiatry. 2012 Apr 15;71(8):700-5
pubmed: 22209637
Chem Biol Interact. 2008 Sep 25;175(1-3):376-9
pubmed: 18514178
J Am Chem Soc. 2008 Sep 10;130(36):12148-55
pubmed: 18710224
Methods Mol Biol. 1999;112:531-52
pubmed: 10027275
Drug Alcohol Depend. 2018 Jul 1;188:295-303
pubmed: 29807217
Bioorg Med Chem Lett. 2017 Aug 15;27(16):3666-3668
pubmed: 28709828
Clin Pharmacol Ther. 1979 Apr;25(4):464-8
pubmed: 428191
Arch Gen Psychiatry. 1984 Sep;41(9):903-9
pubmed: 6431939
J Psychopharmacol. 1998;12(1):15-22
pubmed: 9584964
Biochem J. 2013 Aug 1;453(3):447-54
pubmed: 23849058
Biotechnol J. 2014 Apr;9(4):501-10
pubmed: 24130173
Future Med Chem. 2012 Feb;4(2):125-8
pubmed: 22300091

Auteurs

Katherine E Larrimore (KE)

School of Life Sciences, Arizona State University, Tempe, AZ 85287-4501, USA. Electronic address: Kathy_larrimore@imb.a-star.edu.sg.

Latha Kannan (L)

School of Life Sciences, Arizona State University, Tempe, AZ 85287-4501, USA; Center of Immunotherapy, Vaccines, and Virotherapy, Biodesign Institute, Arizona State University, Tempe, AZ 85287-4501, USA. Electronic address: Latha.Kannan@asu.edu.

R Player Kendle (RP)

School of Life Sciences, Arizona State University, Tempe, AZ 85287-4501, USA. Electronic address: kendle@wisc.edu.

Tameem Jamal (T)

School of Life Sciences, Arizona State University, Tempe, AZ 85287-4501, USA. Electronic address: jamalt@vcu.edu.

Matthew Barcus (M)

School of Life Sciences, Arizona State University, Tempe, AZ 85287-4501, USA. Electronic address: matthew.barcus@wedbush.com.

Kathryn Stefanko (K)

School of Life Sciences, Arizona State University, Tempe, AZ 85287-4501, USA.

Jacquelyn Kilbourne (J)

Center of Immunotherapy, Vaccines, and Virotherapy, Biodesign Institute, Arizona State University, Tempe, AZ 85287-4501, USA. Electronic address: Jacki.Kilbourne@asu.edu.

Stephen Brimijoin (S)

Department of Molecular Pharmacology and Experimental Therapeutics, Mayo Clinic, Rochester, MN 55905, USA. Electronic address: brimijoi@mayo.edu.

Chang-Guo Zhan (CG)

Molecular Modeling and Biopharmaceutical Center and Department of Pharmaceutical Sciences, College of Pharmacy, University of Kentucky, Lexington, KY 40536, USA. Electronic address: chang-guo.zhan@uky.edu.

Janet Neisewander (J)

School of Life Sciences, Arizona State University, Tempe, AZ 85287-4501, USA. Electronic address: janet.neisewander@asu.edu.

Tsafrir S Mor (TS)

School of Life Sciences, Arizona State University, Tempe, AZ 85287-4501, USA; Center of Immunotherapy, Vaccines, and Virotherapy, Biodesign Institute, Arizona State University, Tempe, AZ 85287-4501, USA. Electronic address: tsafrir.mor@asu.edu.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH